The Insight Partners published latest research report on “Structural Heart Market Size Report, Share, Growth, Trends, Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Procedure, and End User” the global market size was valued at USD 14,245.55 million in 2022
The Insight Partners published latest research report on “Structural Heart Market Size Report, Share, Growth, Trends, Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Procedure, and End User” the global market size was valued at USD 14,245.55 million in 2022 and is expected to reach USD 22,560.88 million by 2028; it is estimated to record a CAGR of 8% from 2022 to 2028.
Download PDF Brochure: https://www.theinsightpartners.com/sample/TIPHE100001164
Global Structural Heart Market: Competitive Landscape and Key Developments
Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc., Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomédica Industry, Commerce and Representations Ltd, Aran Biomedical Teoranta, Micro Interventional Devices Inc, and Corcym UK Ltd are among the leading companies operating in the global structural heart market. These players are focusing on diversifying their market presence through product launches and approvals, thereby tapping prevailing business opportunities.
In February 2023, Medtronic announced the relaunch of its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).
In November 2022, Boston Scientific Corporation announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System. The findings, which included a high procedural success rate of 98.4% and low mortality rates and paravalvular leak (PVL), were presented during a late-breaking clinical trial session at PCR London Valves 2022.
In September 2022, Boston Scientific Corporation received the US Food and Drug Administration (FDA) approval to expand the instructions for use labeling for the current-generation WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device to include a 45-day dual antiplatelet therapy (DAPT) option as an alternative to 45-day oral anticoagulation (OAC) plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation (NVAF).
Global Structural Heart Market: Segmental Overview
Based on product, the global structural heart market is segmented into occluders, annuloplasty rings, heart valve balloons, and others. In 2022, the occluders segment held the largest market share in global structural heart market; however, the annuloplasty rings segment is expected to register the highest CAGR during the forecast period. Based on procedure, the structural heart market is segmented into heart valve stenosis, heart valve regurgitation, and left atrial appendage closure. In 2022, the heart valve stenosis segment held the largest share and expected to register the highest CAGR over the forecast period. Based on end user, the global structural heart market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. In 2022, the hospitals segment held the largest market share in global structural heart market, and the same segment is expected to register the highest CAGR during the forecast period.
Quickly Purchase Premium Copy of Structural Heart Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPHE100001164
Global Structural Heart Market Share Report, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 14,245.55 million in 2022 |
| Market Size Value by | USD 22,560.88 million by 2028 |
| Growth rate | CAGR of 8% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
| No. of Pages | 239 |
| No. of Tables | 140 |
| No. of Charts & Figures | 70 |
| Historical data available | Yes |
| Segments covered | Product, Procedure, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | Abbott Laboratories, Medtronic Plc, Boston Scientific Corp, Artivion Inc., Edwards Lifesciences Corp, Lepu Medical Technology Beijing Co Ltd, Braile Biomédica Industry, Commerce and Representations Ltd, Aran Biomedical Teoranta, Micro Interventional Devices Inc, Corcym UK Ltd. |
| Key Research Capabilities | Global Market Assessment, Business Development Strategies, Competitive Landscape, Opportunity Analysis, Regional and Country Level Market Analysis, Market Entry Strategies, Market Dynamics, Risk and Return Assessments, Pricing Analysis, Market Size and Forecasting, Company Profiling, Value Chain Analysis, Expansion Strategies, SWOT Analysis, New Product Development |
Browse key market insights spread across 239 pages with 140 list of tables & 70 list of figures from the report, “Structural Heart Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Occluders, Annuloplasty Rings, Heart Valve Balloons, and Others), Procedure (Heart Valve Stenosis, Heart Valve Regurgitation, and Left Atrial Appendage Closure), and End User (Hospitals, Ambulatory Surgical Centers, and Cardiac Centers)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/structural-heart-devices-market
Global Structural Heart Market - Future Trends
Technological Advancements in the Field of Structural Heart Devices:
Transcatheter procedures lead to improvements in patients’ heart conditions in a shorter period compared to surgical intervention. In addition, minimally invasive procedures have reduced surgical and cardiopulmonary risks, which results in increased patient satisfaction. TAVR has gathered more attention due to its ability to offer a reasonable option for the treatment of degenerative aortic stenosis. In 2017, Edwards Lifesciences’s Edwards Sapien valve was under several studies in the PARTNER trial. The valve has been made from a bovine pericardial tissue valve, and it is sutured on a cobalt–chromium stent scaffold. The stent allows the maximum possible folding of the valve, which allows the maintenance of structural and radial support once it is expanded. Moreover, the recent developments in structural heart devices focus on indications, and results of left atrial appendage (LAA) and patent foramen ovale (PFO) closure to prevent cardioembolic stroke. A few of the technological advancements by the players in the structural heart market are mentioned below:
• In February 2023, Medtronic announced the relaunch of its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired RVOT.
• In September 2022, Medtronic announced the expansion of the release of its newest-generation, self-expanding TAVR system—the Evolut FX TAVR system—in the US. Evolut FX added new features to the existing Evolut platform to enhance ease of use and predictable valve deployment for physicians.
• In May 2022, Philips launched EchoNavigator 4.0, the new release of its image-guided therapy solution, for the treatment of structural heart disease. EchoNavigator 4.0 provides the users of Philips’ EPIQ CVXi interventional cardiology ultrasound system a control of live fusion-imaging on the company’s Image Guided Therapy System called “Azurion–platform.”
• In September 2021, Abbott received FDA approval for its Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
North America holds the largest share of the global structural heart market. The market growth in this region is attributed to a few factors such as the rise in the prevalence of heart diseases, an increase in the number of regulatory approvals, research & development, and new product launches. The US holds the largest market in the North America structural heart market. According to the Cleveland Clinic, heart valve disease affects ~2.5% of people in the US. These include valve regurgitation (leaky) or stenosis (narrowing). According to the American Heart Association, in 2022, 1 in 500 people in the US can have hypertrophic cardiomyopathy. Cardiomyopathy has many causes, including coronary artery disease, consequences of a viral infection, environmental influences (e.g., alcohol), and hereditary causes. The most common type of congenital disability in the US is known to be congenital heart defects (CHDs). According to the Centers for Disease Control and Prevention (CDC), ~1% of 40,000 births annually is affected by CHDs. Also, it is stated that ~25% of babies suffer from severe CHDs and require surgical treatment. According to the Centers for Disease Control and Prevention (CDC), ~735,000 Americans have a heart attack every year, out of which 525,000 patients recorded their first heart attack while 210,000 patients already had a heart attack in the past. According to the US Census Bureau, 2.5 million people in the US over the age of 75 suffer from aortic stenosis, accounting for 12.4% of the population over 75 years of age. An article published in American Heart Association’s journal stated that mitral regurgitation is the most frequent valve disease in the US. It affects approximately 1 in 10 people that are 75 years or older. Furthermore, the Society for Cardiovascular Angiography and Interventions Foundation conducts structural training programs in the US. Such factors are expected to bolster the structural heart market in the US.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Structural Heart Disease Treatment Devices Professional Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Heart Rate Monitoring Device Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Household Heart Monitoring Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product
Heart Tumor Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Heart Failure Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis
Tissue Engineered Heart Valve Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Heart Transplant Market Forecast to 2028 - COVID-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/structural-heart-devices-market